Home » Newsletters » BioWorld Science

BioWorld Science

July 15, 2003

View Archived Issues

New bradykinin B2 antagonists and their use as analgesics reported by AstraZeneca

Piperazine orexin antagonists in early development at GSK

New JNK inhibitors with utility in AD therapy reported in recent patent

Gruenenthal patent covers new alpha2A-AR ligands for pain and other uses

Novel methionine aminopeptidase type 2 inhibitors discovered by GSK scientists

AstraZeneca claims new cannabinoid CB1 receptor modulators

New alpha7 nAChR agonists under study at Bayer

AVP-893: a prototype of a novel class of antitumor agents designed at Avanir

Selective small-molecule inhibitors of CDK4 identified at Roche

Roche presents new series of antitumor agents targeting CDK2

Orally available Src tyrosine kinase inhibitor characterized in vitro and in vivo

Further preclinical characterization of AG-013736, a VEGFR/PDGFR TK inhibitor

VEGF receptor tyrosine kinase inhibitor E-7080, a promising agent for solid tumors

Efaproxiral reported to improve survival in cancer patients with brain metastases

MEDI-507 proven effective in a murine model of adult T-cell leukemia

Improved survival with carvedilol compared to metoprolol in chronic heart failure

Synthetic Hsp90 ATPase inhibitor identified as potential new lead anticancer agent

Barrier Therapeutics licenses oral vitamin D3 derivative

Genmab expands pipeline with hepatitis antibody

Phase II clinical trial of advanced malaria vaccine to begin in Mozambique

United Therapeutics files IND for i.v. Remodulin

Encouraging results from ongoing phase I/II trial with MetXia in breast cancer

Aastrom Biosciences receives third NIH grant for stem cell research

FDA clears phase I study of PHP as an adjunct to IL-2 cancer therapy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ASH 2025: New blood cancer therapies trump chemo, older drugs
BioWorld
Targeted therapies and immunotherapies continue to show better results than chemotherapy in investigator-initiated and company-sponsored cancer trials, and newer...